首页|氢吗啡酮复合罗哌卡因腰硬联合阻滞用于妊娠期高血压产妇分娩镇痛的临床研究

氢吗啡酮复合罗哌卡因腰硬联合阻滞用于妊娠期高血压产妇分娩镇痛的临床研究

扫码查看
目的 探讨氢吗啡酮复合罗哌卡因腰硬联合阻滞用于妊娠期高血压产妇分娩镇痛的价值。方法 选择 90 例单胎、合并妊娠期高血压的初产妇作为研究对象,随机分成H1 组(氢吗啡酮10 μg/ml+0。1%罗哌卡因)、H2 组(氢吗啡酮 15 μg/ml+0。1%罗哌卡因)、F组(芬太尼 2 μg/ml+0。1%罗哌卡因),各 30 例。三组的腰麻用药均为 0。1%罗哌卡因 3 mg。比较三组产妇分娩镇痛前(T0)、镇痛后5 min(T1)、镇痛后 30 min(T2)、镇痛后 1 h(T3)、镇痛后 2 h(T4)、宫口开全(T5)、胎儿娩出(T6)时的视觉模拟评分法(VAS)评分及平均动脉压(MAP),总产程时间、分娩方式、新生儿Apgar评分,运动阻滞情况、不良反应发生情况、产时发热情况及满意度。结果 三组产妇VAS评分在T0 时无明显差异(P>0。05),三组产妇T1~T6时VAS评分均较T0时下降(P<0。05);H1组和H2组产妇在T3~T6时VAS评分均明显低于F组(P<0。05),而H1组与H2组产妇在T3~T6时VAS评分比较无明显差异(P>0。05)。三组产妇MAP在T1~T6时较T0时均降低(P<0。05)。三组产妇总产程时间、分娩方式及新生儿1、5 min Apgar评分无明显差异(P>0。05)。三组产妇改良Bromage评分0级占比和产时发热占比比较无明显差异(P>0。05);H1组产妇不良反应发生率10。0%低于H2组的33。3%和F组的36。7%,总满意率93。3%高于H2组的66。7%和F组的66。7%(P<0。05)。结论 10 μg/ml氢吗啡酮+0。1%罗哌卡因硬膜外自控镇痛联合0。1%罗哌卡因3 mg蛛网膜下腔阻滞镇痛起效快、镇痛效果好、不良反应少,可安全用于妊娠期高血压产妇的分娩镇痛。
Clinical study of combined spinal and epidural block with hydromorphone and ropivacaine for labor analgesia in women with pregnancy-induced hypertension
Objective To explore the value of combined spinal and epidural block with hydromorphone and ropivacaine for labor analgesia in women with pregnancy-induced hypertension.Methods 90 primiparous women with singleton pregnancy and pregnancy-induced hypertension were selected as study subjects and randomly divided into group H1(hydromorphone 10 μg/ml+0.1%ropivacaine),group H2(hydromorphone 15 μg/ml+0.1%ropivacaine),and group F(fentanyl 2 μg/ml+0.1%ropivacaine),with 30 cases in each group.All three groups received 0.1%ropivacaine 3 mg for lumbar anesthesia.Comparison was made on visual analogue scale(VAS)score and mean arterial pressure(MAP)before analgesia(T0),5 min after analgesia(T1),30 min after analgesia(T2),1 h after analgesia(T3),2 h after analgesia(T4),complete dilation of the cervix(T5)and fetal delivery(T6),total duration of labor,mode of delivery,neonatal Apgar score,motor block,occurrence of adverse reactions,intrapartum fever and satisfaction among the three groups.Results The VAS scores of the three groups had no significant difference at T0(P>0.05),and decreased at T1-T6 compared with T0(P<0.05).The VAS scores in group H1 and group H2 were significantly lower than those in group F at T3-T6(P<0.05),but there was no significant difference in VAS scores between group H1 and group H2 at T3-T6(P>0.05).Compared with T0,MAP of the three groups was decreased at T1-T6(P<0.05).There were no significant differences in the total duration of labor,mode of delivery and Apgar score at 1 min and 5 min after birth among the three groups(P>0.05).There was no significant difference in the percentage of modified Bromage grade 0 and intrapartum fever among the three groups(P>0.05).The incidence rate of maternal adverse reactions in group H1 was 10.0%,which was lower than that in group H2(33.3%)and group F(36.7%);and the overall satisfaction rate was 93.3%,which was higher than that in group H2(66.7%)and group F(66.7%)(P<0.05).Conclusion 10 μg/ml hydromorphone+0.1%ropivacaine patient-controlled epidural analgesia combined with 0.1%ropivacaine 3 mg subarachnoid block analgesia has a fast onset of action,good analgesic effect,and fewer adverse reactions,and can be safely used for labor analgesia in women with pregnancy-induced hypertension.

HydromorphoneRopivacaineCombined spinal and epidural blockPregnancy-induced hypertensionPostpartum womenLabor analgesia

吕承志、张丽峰、张伟娜、宋修响

展开 >

266200 青岛市即墨区人民医院麻醉科

氢吗啡酮 罗哌卡因 腰硬联合阻滞 妊娠期高血压 产妇 分娩镇痛

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(22)